07 May 2021 : Clinical Research
Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis
DOI: 10.12659/MSM.928784
Med Sci Monit 2021; 27:e928784